专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006089697B1 METHOD FOR DETERMINING THE TOTAL COAGULATION ACTIVITY OF A BLOOD OR PLASMA SAMPLE 审中-公开
标题翻译：一种用于确定血液或血浆样品的总凝血活性
公开(公告)号：WO2006089697B1
公开(公告)日：2006-10-26
申请号：PCT/EP2006001492
申请日：2006-02-17
申请人： HAEMOSYS GMBH , NOWAK GOETZ , BUCHA ELKE , LANGE UTE
发明人： NOWAK GOETZ , BUCHA ELKE , LANGE UTE
IPC分类号： G01N33/86
CPC分类号： G01N33/86 , G01N2333/811 , G01N2333/815 , G01N2333/974
摘要： The invention relates to a method for determining the total coagulation activity of a blood or plasma sample. Said method is characterised in that a defined quantity of a highly-specific, non-irreversible thrombin inhibitor is added to a blood or plasma sample, the coagulation in the blood or plasma sample is induced, and after a defined period of time, the consumed quantity of the added thrombin inhibitor is determined by methods known per se. The invention also relates to a kit for obtaining information about the coagulation status of a blood sample.
摘要翻译：本发明涉及一种用于确定血液或血浆样品的总凝血活性，其特征在于，加入了高度特异性的，不可逆凝血酶在一个限定的血液或血浆样品的量的抑制剂，诱导血液或血浆样品中的凝固和通过时间限定所添加的凝血酶抑制剂的测定中以常规方式消耗量和试剂盒获得关于血样的凝固状态语句。

2. 发明申请

WO1997010509A1 COMPLEX-BOUND INHIBITORS OF METABOLIC ENZYMES CAPABLE OF BEING ACTIVATED, USEFUL AS MOLECULAR MARKERS FOR DIAGNOSTIC AND THERAPY MONITORING PURPOSES 审中-公开
标题翻译：复杂绑定的抑制剂可激活代谢酶作为诊断和治疗监测的分子标记
公开(公告)号：WO1997010509A1
公开(公告)日：1997-03-20
申请号：PCT/EP1996003383
申请日：1996-08-01
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., BERLIN , NOWAK, Götz , BUCHA, Elke , BALDINGER, Verena
发明人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., BERLIN
IPC分类号： G01N33/86
CPC分类号： G01N33/86 , G01N2333/811 , G01N2333/8121 , G01N2333/8132 , G01N2333/815
摘要： An inhibitor bound to a substrate of high molecular weight inhibits a metabolic enzyme capable of being activated and is useful as molecular marker to determine the activation of said enzyme and diagnose the presence of said enzyme. Also disclosed is the use of a thrombin inhibitor bound to a substrate of high molecular weight as molecular marker to detect coagulation activation for the purpose of diagnosing coagulation and monitoring a therapeutic treatment. Preferably, the use of dextran-hirudine or PEG-coupled hirudine as molecular marker is disclosed for diagnosing coagulation and monitoring a therapeutic treatment.
摘要翻译：本发明涉及使用一个绑定的可活化的代谢酶的分子量大载体抑制剂作为用于确定这种酶的活化的酶的诊断分子标记。特别地，本发明涉及使用一个绑定到一个大分子量载体凝血酶抑制剂作为凝血诊断和治疗监测确定凝血激活的分子标记。优选地，本发明涉及使用葡聚糖 - 水蛭素或PEG-耦合水蛭素作为用于凝固的诊断和治疗监测分子标记。

3. 发明申请

WO2012077097A1 IMMUNOASSAY FOR THROMBIN DETECTION 审中-公开
标题翻译：免疫检测用于血栓检测
公开(公告)号：WO2012077097A1
公开(公告)日：2012-06-14
申请号：PCT/IL2011/000911
申请日：2011-11-30
申请人： OMRIX BIOPHARMACEUTICALS LTD. , MINTZ, Roni , ORR, Nadav , NUR, Israël
发明人： MINTZ, Roni , ORR, Nadav , NUR, Israël
IPC分类号： G01N33/86
CPC分类号： G01N33/573 , C07K16/36 , G01N33/86 , G01N2333/8128 , G01N2333/815 , G01N2333/974
摘要： The invention relates to an in vitro immunoassay for quantifying thrombin in a sample comprising anti-thrombin III (AT-III) and thrombin. The method comprises the following steps: contacting the sample with a small molecule that recognizes the substrate binding site of thrombin; contacting the thrombin with a thrombin specific antibody raised against a thrombin blocked in the active site; and measuring the level of bound antibody.
摘要翻译：本发明涉及在含有抗凝血酶III（AT-III）和凝血酶的样品中定量凝血酶的体外免疫测定。该方法包括以下步骤：使样品与识别凝血酶底物结合位点的小分子接触; 使凝血酶与在活性部位阻断的凝血酶产生的凝血酶特异性抗体接触; 并测量结合抗体的水平。

4. 发明申请

WO99043688A1 PHOTOACTIVATABLE NUCLEIC ACID DERIVATIVES 审中-公开
标题翻译：可摄取的核酸衍生物
公开(公告)号：WO99043688A1
公开(公告)日：1999-09-02
申请号：PCT/US1999/003862
申请日：1999-02-23
IPC分类号： A61L27/00 , A61L27/14 , A61L27/34 , A61L29/04 , A61L29/08 , A61L31/04 , A61L31/10 , A61L33/00 , C07H21/00 , C08L33/26 , C12N11/08 , C12N15/09 , C12Q1/56 , C12Q1/68 , G01N33/53 , G01N33/543 , G01N33/68 , G01N37/00 , C07H1/08
CPC分类号： C07H21/00 , A61L27/14 , A61L27/34 , A61L29/04 , A61L29/085 , A61L31/04 , A61L31/10 , A61L33/0011 , A61L33/0047 , C12N11/08 , C12Q1/56 , C12Q1/6834 , G01N33/543 , G01N33/68 , G01N33/6845 , G01N33/6854 , G01N2333/78 , G01N2333/8128 , G01N2333/815 , G01N2333/974
摘要： A photoactivatable nucleic acid derivative composition in which one or more photoreactive group(s) are bound to a natural or synthetic nucleic acid. The photoreactive groups can be bound to the nucleic acid before, during or after its formation, and can thereafter be activated in order to attach the nucleic acid to another molecule, e.g., to the surface of a solid support. Also described is a method of preparing such a composition, and a method of using such a composition to attach the nucleic acid to another molecule, such as that provided by the surface of a substrate used to prepare a nucleic acid chip by photolithographic techniques.
摘要翻译：一种可光活化的核酸衍生物组合物，其中一个或多个光反应基团与天然或合成核酸结合。光反应性基团可以在其形成之前，期间或之后与核酸结合，然后可以活化以将核酸附着到另一个分子，例如固体支持物的表面。还描述了制备这种组合物的方法，以及使用这样的组合物将核酸附着到另一分子上的方法，例如由用于通过光刻技术制备核酸芯片的底物的表面提供的。

5. 发明申请

WO1997044661A1 METHOD OF CARRYING OUT BLOOD TESTS 审中-公开
标题翻译：制法验血
公开(公告)号：WO1997044661A1
公开(公告)日：1997-11-27
申请号：PCT/EP1997002343
申请日：1997-05-07
申请人： RHEIN BIOTECH GESELLSCHAFT FÜR NEUE BIOTECHNOLOGISCHE PROZESSE UND PRODUKTE MBH , UNIVERSITÄTSKLINIKUM BENJAMIN FRANKLIN , STRASSER, Alexander, W., M. , MELBER, Karl , MENSSEN, Hans, Dietrich , THIEL, Eckard
发明人： RHEIN BIOTECH GESELLSCHAFT FÜR NEUE BIOTECHNOLOGISCHE PROZESSE UND PRODUKTE MBH , UNIVERSITÄTSKLINIKUM BENJAMIN FRANKLIN
IPC分类号： G01N33/50
CPC分类号： G01N33/50 , G01N33/86 , G01N2333/815 , Y10T436/108331
摘要： The invention concerns a method of carrying out blood tests. The invention is based on the knowledge that clinico-chemical blood parameters can be determined using not only blood serum but also blood plasma. Therefore, freshly taken blood samples, which are mixed with at least one thrombin inhibitor, can be used for determining both clinico-chemical parameters and haematological parameters. The clinico-chemical parameters can thus be determined using blood plasma, separation of coagulable components no longer being necessary.
摘要翻译：本发明涉及一种用于执行血液测试的方法。本发明是基于血液化学参数，不仅可以使用血清，也使用血浆来确定的发现。因此，新鲜的血液样品可以被使用，其与至少一种凝血酶抑制剂处理，既可用于临床化学参数的确定和用于确定血液学参数。临床化学参数因此可以使用血浆确定; 分离凝固性部件不再是必需的。

6. 发明申请

WO1993016390A1 METHOD OF DETERMINING HIRUDIN AND SYNTHETIC THROMBIN INHIBITORS 审中-公开
标题翻译：方法确定呼伦贝红和合成脑啡肽抑制剂
公开(公告)号：WO1993016390A1
公开(公告)日：1993-08-19
申请号：PCT/EP1993000161
申请日：1993-01-25
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER ... , NOWAK, Götz , BUCHA, Elke , HOFFMANN, Jutta
发明人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER ...
IPC分类号： G01N33/86
CPC分类号： C12Q1/56 , G01N2333/4633 , G01N2333/815 , G01N2333/974
摘要： The invention concerns a method for the determination of hirudin and synthetic thrombin inhibitors in blood or in constituents of blood. In this method, a prothrombin intermediate, a compound which splits prothrombin into meizothrombin, a salt thereof or a mixture of these compounds plus, optionally, buffers and/or other customary additives are added to the blood or blood constituents and the time from addition to the point at which coagulation begins is measured. The invention also concerns means for carrying out the method, the means including a prothrombin intermediate, a compound which splits prothrombin into meizothrombin, a salt thereof or a mixture of these compounds plus, optionally, buffers and/or other customary additives.

7. 发明申请

WO2006089697A1 VERFAHREN ZUR BESTIMMUNG DER GESAMTGERINNUNGSAKTIVITÄT EINER BLUT- ODER PLASMAPROBE 审中-公开
标题翻译：确定血液或血浆探针总回收率的方法
公开(公告)号：WO2006089697A1
公开(公告)日：2006-08-31
申请号：PCT/EP2006/001492
申请日：2006-02-17
申请人： HAEMOSYS GMBH , NOWAK, Götz , BUCHA, Elke , LANGE, Ute
发明人： NOWAK, Götz , BUCHA, Elke , LANGE, Ute
IPC分类号： G01N33/86
CPC分类号： G01N33/86 , G01N2333/811 , G01N2333/815 , G01N2333/974
摘要： Die Erfindung betrifft ein Verfahren zur Bestimmung der Gesamtgerinnungsaktivität einer Blut- oder Plasmaprobe, dadurch gekennzeichnet, dass man einen hochspezifischen, nicht irreversiblen Thrombinhemmstoff in definierter Menge einer Blut- oder Plasmaprobe zusetzt, die Gerinnung in der Blut- oder Plasmaprobe induziert und nach einer definierten Zeit die verbrauchte Menge des zugesetzten Thrombinhemmstoffs in an sich bekannter Weise bestimmt sowie ein Kit zum Erhalt von Aussagen über den Gerinnungsstatus einer Blutprobe.
摘要翻译：
本发明涉及一种方法，用于确定Gesamtgerinnungsaktivit＆AUML;吨血液或血浆样品，其特征在于，加入了高度特异性的，不可逆凝血酶抑制剂在一个限定的血液或血浆样品的量，在凝固诱导的血液或血浆样品和限定的时间和用于获得语句导航使用的试剂盒确定后以传统方式添加的凝血酶抑制剂的消耗量。关于血样的凝固状态

8. 发明申请

WO1993025220A1 TEST FOR QUANTITATIVE THROMBIN TIME 审中-公开
标题翻译：测量定量血栓时间
公开(公告)号：WO1993025220A1
公开(公告)日：1993-12-23
申请号：PCT/US1993005297
申请日：1993-06-02
申请人： REID, Thomas, J., III , ALVING, Barbara, M.
IPC分类号： A61K37/02
CPC分类号： C12Q1/56 , C07K14/815 , G01N2333/815 , G01N2333/974 , G01N2400/40
摘要： A quantitative method for determining the plasma levels of thrombin-specific inhibitors is based on the quantitative thrombin time using plasma dilutions, excess fibrinogen and thrombin. The plasma dilutions and excess fibrinogen act in concert to eliminate the effects that coagulopathies have on standard coagulation tests. The method is relatively simple and provides superior results to standard conventional tests. The method is suitable for performance in clinical hematology laboratories on a routine basis using commercially available instrumentation.
摘要翻译：用于确定凝血酶特异性抑制剂的血浆水平的定量方法基于使用血浆稀释度，纤维蛋白原过量和凝血酶的凝血酶形成时间的定量测量。血浆稀释液和过量的纤维蛋白原一起工作以抑制凝血病对标准凝血分析的影响。该方法相对简单，产生的结果优于标准标准测试。该方法可以常规应用于临床血液学实验室，使用市售仪器。

9. 发明申请

WO1992007954A1 A METHOD TO DETERMINE THE CONCENTRATION OF ANTICOAGULANTS 审中-公开
标题翻译：一种确定抗凝剂浓度的方法
公开(公告)号：WO1992007954A1
公开(公告)日：1992-05-14
申请号：PCT/US1991008117
申请日：1991-10-30
申请人： BAXTER DIAGNOSTICS INC.
发明人： BAXTER DIAGNOSTICS INC. , HEMKER, Hendrik, Coenraad , WAGENVOORD, Robert, Johan , KOLDE, Hans-Jurgen
IPC分类号： C12Q01/56
CPC分类号： C12Q1/56 , G01N2333/815 , G01N2333/974 , G01N2400/40
摘要： The present invention relates to a method to determine the concentration of anticoagulants as a function of the inhibition of thrombin formation in an assay mixture. The assay mixture is composed of two reagents and the diluted plasma sample. The diluted plasma sample containing an anticoagulatory substance is mixed with a clotting factor reagent, which is a combination of an excess amount of purified coagulation factors of the endogenous system, phospholipids and a weak thrombin inhibitor, which can be potentiated by an anticoagulatory substance. Then a coagulation cascade activator and calcium chloride, an activator reagent, is added to the mixture and formed thrombin is measured after a chosen incubation time. A proportionality between the inhibition of the thrombin formation and the anticoagulatory active components allows for a determination of the concentration of anticoagulatory active components in the sample.
摘要翻译：本发明涉及一种确定抗凝血剂浓度作为测定混合物中凝血酶形成抑制的函数的方法。测定混合物由两种试剂和稀释的血浆样品组成。含有抗凝物质的稀释血浆样品与凝血因子试剂混合，凝血因子试剂是过量的内源性系统的纯化凝血因子，磷脂和弱凝血酶抑制剂的组合，其可以被抗凝物质加强。然后将凝血级联活化剂和氯化钙（活化剂）加入到混合物中，并在选择的孵育时间后测量形成的凝血酶。抑制凝血酶形成与抗凝活性成分之间的比例允许测定样品中抗凝活性成分的浓度。

10. 发明申请

WO9908717A3 LATENT REACTIVE POLYMERS WITH BIOLOGICALLY ACTIVE MOIETIES 审中-公开
标题翻译：具有生物活性物质的最终反应性聚合物
公开(公告)号：WO9908717A3
公开(公告)日：1999-05-06
申请号：PCT/US9816605
申请日：1998-08-11
申请人： SURMODICS INC
发明人： CLAPPER DAVID L , SWANSON MELVIN J , HU SHEAU-PING , AMOS RICHARD A , EVERSON TERRENCE P
IPC分类号： A61L27/00 , A61L27/14 , A61L27/34 , A61L29/04 , A61L29/08 , A61L31/04 , A61L31/10 , A61L33/00 , C08J7/12 , C08L33/26 , C12N11/08 , C12Q1/00 , C12Q1/56 , C12Q1/68 , G01N33/543 , G01N33/68 , G03F7/004 , C08L101/00
CPC分类号： G01N33/6845 , A61L27/14 , A61L27/34 , A61L29/04 , A61L29/085 , A61L31/04 , A61L31/10 , A61L33/0011 , A61L33/0047 , C08J7/12 , C12N11/08 , C12Q1/56 , C12Q1/6834 , G01N33/54353 , G01N33/54366 , G01N33/68 , G01N33/6854 , G01N2333/78 , G01N2333/8128 , G01N2333/815 , G01N2333/974 , Y10S530/815 , Y10S530/816
摘要： A polybifunctional reagent having a polymeric backbone, one or more pendent photoreactive moieties, and two or more pendent bioactive groups. The reagent can be activated to form a bulk material or can be brought into contact with the surface of a previously formed biomaterial and activated to form a coating. The pendent bioactive groups function by promoting the attachment of specific molecules or cells to the bulk material or coated surface. Bioactive groups can include proteins, peptides, carbohydrates, nucleic acids and other molecules that are capable of binding noncovalently to specific and complimentary portions of molecules or cells.
摘要翻译：具有聚合物主链，一个或多个侧基光反应性部分和两个或更多个侧链生物活性基团的多功能试剂。试剂可以被活化以形成散装材料，或者可以与先前形成的生物材料的表面接触并活化以形成涂层。悬浮生物活性基团通过促进特定分子或细胞附着到大块材料或涂层表面而起作用。生物活性基团可以包括蛋白质，肽，碳水化合物，核酸和能够非共价结合分子或细胞的特定和互补部分的其它分子。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式